Natural sugar defends against metabolic syndrome, in mice

August 23, 2018

New research, in mice, indicates that a natural sugar called trehalose blocks glucose from the liver and activates a gene that boosts insulin sensitivity, reducing the chance of developing diabetes. Activating the gene also triggers an increase in calories burned, reduces fat accumulation and weight gain, and lessens measures of fats and cholesterol in the blood.

The findings, from researchers at Washington University School of Medicine in St. Louis, suggest new possibilities for treating metabolic syndrome, a cluster of related conditions that includes obesity, diabetes and fatty liver disease.

The study is published Aug. 23 in JCI Insight.

While potential medicinal use of trehalose still requires considerable research, the investigators found that giving mice trehalose via drinking water resulted in beneficial effects on the animals' liver metabolism -- similar to benefits that resulted from fasting. In fasting mice, the liver also turns on the same gene that improves the body's ability to use insulin.

"We learned that this gene, Aloxe3, improves insulin sensitivity in the same way that common diabetes drugs -- called thiazolidinediones -- improve insulin sensitivity," said Brian DeBosch, MD, PhD, an assistant professor of pediatrics. "And we showed that Aloxe3 activation in the liver is triggered by both trehalose and by fasting, possibly for the same reason: depriving the liver of glucose.

"In mice, this gene is turned on as part of what seems to be the normal fasting response. Our data suggest that fasting -- or giving trehalose with a normal diet -- triggers the liver to change the way it processes nutrients, in a beneficial way. And if glucose can be blocked from the liver with a drug, it may be possible to reap the benefits of fasting without strictly limiting food."

The researchers found that Aloxe3 in the liver -- whether activated by fasting or trehalose -- leads the mice not only to make better use of insulin, but to increase calorie burning, raise body temperature, reduce weight gain and fat accumulation -- including fat deposits in the liver -- and lessen measures of fats and cholesterol in the blood. Further, they found that mice fed an obesity-inducing diet and mice that eat freely and are genetically prone to obesity are protected from metabolic disease if given trehalose in their drinking water.

Studying the genes switched on in the livers of mice given trehalose, DeBosch and his colleagues became intrigued by Aloxe3, which typically is known for helping the skin maintain proper hydration in the body and had not been thought to have any role in the liver.

The researchers found that activating Aloxe3 in the mice given trehalose improves insulin sensitivity in a way that is similar to how thiazolidinediones work. Studying healthy mice given only water over a 48-hour period, they found that fasting, likewise, activates Aloxe3 in the liver. This activation could boost insulin sensitivity in the same way.

However, DeBosch said, trehalose may encounter enzymes in the digestive tract that break it apart, releasing its two glucose molecules, which would be counterproductive. The researchers investigated a similar sugar -- lactotrehalose -- they found has the same beneficial effects from triggering Aloxe3 but does not break apart as easily.
-end-
This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program, award number W81XWH-17-1-0133. This work also was supported by the National Institutes of Health (NIH), grant numbers UL1TR002345, P30DK52574, P30DK020579, P30DK056341, K12HD076224, R15 AI117670 and T32GM007067; the Children's Discovery Institute, grant number MI-FR-2014-426; the AGA-Gilead Sciences Research Scholar Award in Liver Disease; the Robert Wood Johnson Foundation; the Washington University Spencer T. Olin Fellowship; and National Science Foundation Graduate Student Fellowship, grant number DGE-1143954. Herbert Virgin and David Rudnick provided specific mouse strains.

Higgins CB, Zhang Y, Mayer AL, Fujiwara H, Stothard AI, Graham MJ, Swarts BM, DeBosch BJ. Aloxe3 is a hepatic fasting-responsive lipoxygenase that enhances insulin sensitivity via hepatic PPAR-gamma. Aug. 23, 2018.

Washington University School of Medicine's 1,300 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Washington University School of Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.